Container closure integrity (CCI) is the foundational assurance that a parenteral drug packaging system maintains its sterile barrier — preventing microbial ingress, product loss, and contaminant entry — throughout the full product lifecycle from manufacturing through distribution and patient use. Yet CCI is not a binary condition: it is defined relative to a product-specific maximum allowable leakage limit (MALL), the smallest leak rate that jeopardizes product quality, and must be assessed using test methods whose sensitivity, destructiveness, and applicability are matched to the specific container system, drug product, and storage conditions at hand. This on-demand webinar, part of Datwyler's P.E.R.F.E.C.T.-ing the Pharmaceutical Packaging Selection Process series, provides a rigorous end-to-end framework for CCI across parenteral packaging systems. The session establishes the critical distinction between package integrity (absence of a breach that could risk product quality) and product sterility, and reviews the regulatory landscape — USP <1207>, USP <382>, and EU GMP Annex 1 — that governs CCI testing requirements. Four CCI test methods are examined in technical depth: dye ingress (qualitative, destructive, probabilistic, ~20 µm sensitivity, susceptible to drug product interference); high voltage leak detection (HVLD, quantitative, non-destructive, deterministic, ~5 µm, limited to conductive non-lyophilized products without metal components); laser-based headspace CO₂ analysis (quantitative, non-destructive, deterministic, ~0.1 µm, uniquely suited for cold storage applications to -80°C); and helium leak detection (HLD, quantitative, destructive, deterministic, ~0.01 µm, with the Kirsch criterion of 1.6×10⁻⁶ mbar·L/s as the pass/fail threshold and demonstrated correlation to residual seal force values for vial stoppers). Development-stage CCI considerations covered include container system pre-selection, cold chain shipping simulation, and second sourcing qualification strategies.
.png)
